INSYS Therapeutics Inc. (INSY)

0.30
0.01 4.52
OTC : Health Technology
Prev Close 0.29
Open 0.28
Day Low/High 0.28 / 0.32
52 Wk Low/High 0.14 / 11.65
Volume 1.09M
Avg Volume 3.70M
Exchange OTC
Shares Outstanding 74.57M
Market Cap 21.71M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Insys Therapeutics, Inc. - INSY

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Insys Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Insys Therapeutics, Inc. - INSY

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Insys Therapeutics, Inc.

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Insys Therapeutics, And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Insys Therapeutics, Inc.

Insys Falls on Earnings Delay

Insys Falls on Earnings Delay

Shares of Insys Therapeutics INSY tumbled Thursday after the company revealed that it would be reporting fourth quarter earnings later than expected thanks to delays from its audit committee.

Insys Therapeutics Announces Delay In The Release Of Its Fourth Quarter And Full Year 2016 Results

-- Fourth Quarter 2016 Net Sales Estimated at $54 million --

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

These heavily shorted stocks could get squeezed higher if they report positive earnings this week.

Short Interest Drops 14.7% For INSY

The most recent short interest data has been released for the 02/28/2017 settlement date, which shows a 2,019,716 share decrease in total short interest for Insys Therapeutics Inc , to 11,726,537, a decrease of 14.69% since 02/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Insys Therapeutics Shares Cross Above 200 DMA

In trading on Wednesday, shares of Insys Therapeutics Inc crossed above their 200 day moving average of $12.92, changing hands as high as $13.56 per share. Insys Therapeutics Inc shares are currently trading up about 6.7% on the day.

Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs

Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs

Cannabis stocks are not affected by the volatility in prices during earnings season and instead trade on positive data such as potential FDA approval on their pipeline of drugs.

Interesting INSY Put And Call Options For March 17th

Interesting INSY Put And Call Options For March 17th

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

Insys Therapeutics Enters Oversold Territory (INSY)

Insys Therapeutics Enters Oversold Territory (INSY)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

The Worst Biopharma CEOs of 2016 Are ...

The Worst Biopharma CEOs of 2016 Are ...

There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.

INVESTOR ALERT: Investigation Of Insys Therapeutics Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Insys Therapeutics Announced By Holzer & Holzer

On December 8, 2016, six former executives of Insys Therapeutics, Inc.

Canadian Marijuana Market More Mature, Outperforms U.S. Market

Canadian Marijuana Market More Mature, Outperforms U.S. Market

The Canadian marijuana market is poised for growth as the number of registered patients continues grows and as licensed producers find innovative ways to create value for its shareholders.

4 Stocks You Can Buy to Profit From the Rising Use of Medical Marijuana

4 Stocks You Can Buy to Profit From the Rising Use of Medical Marijuana

GW Pharmaceuticals has developed cannabis-based therapies for treating epilepsy and multiple sclerosis.

'Mad Money' Lightning Round: American Electric Power, Amgen, Dow Chemical

'Mad Money' Lightning Round: American Electric Power, Amgen, Dow Chemical

Jim Cramer finds reasons to like AEP, AMGN, DOW and HEI.

Jim Cramer's 'Mad Money' Recap: We've Been Afraid of Higher Rates for Years

Jim Cramer's 'Mad Money' Recap: We've Been Afraid of Higher Rates for Years

This rally isn't just about Trump, Cramer says. He thinks investors are cheering the economic outlook.

Commit To Buy Insys Therapeutics At $9, Earn 22.4% Annualized Using Options

Commit To Buy Insys Therapeutics At $9, Earn 22.4% Annualized Using Options

Investors eyeing a purchase of Insys Therapeutics Inc stock, but tentative about paying the going market price of $12.78/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $9 strike, which has a bid at the time of this writing of 95 cents.

Three Pot Stocks to Watch for 2017

Three Pot Stocks to Watch for 2017

Donald Trump was not the only big winner on Election Day. The cannabis industry got a spark as well.

Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector

Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector

President-elect Trump's vague healthcare policy has put the $3 trillion industry on edge.

Even in a Trump Presidency, Marijuana Is a Good Investment

Even in a Trump Presidency, Marijuana Is a Good Investment

The U.S. president elect has said in the past that he favors the legalization of marijuana, and he is unlikely to change his stance significantly.